Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention | Zendy

Yiming M. Zhu | Zendy; Todd J. Anderson | Zendy; Khokan C. Sikdar | Zendy; Marinda Fung | Zendy; Matthew McQueen | Zendy; Eva Lonn | Zendy; Subodh Verma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention

Author(s) -

Yiming M. Zhu,

Todd J. Anderson,

Khokan C. Sikdar,

Marinda Fung,

Matthew McQueen,

Eva Lonn,

Subodh Verma

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306172

Subject(s) - kexin , pcsk9 , proprotein convertase , subtilisin , medicine , proprotein convertases , primary prevention , evolocumab , ldl receptor , endocrinology , cholesterol , disease , biology , lipoprotein , biochemistry , enzyme , apolipoprotein a1

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of low-density lipoprotein metabolism. This study was conducted to evaluate the relationship between serum PCSK9 concentrations and measures of vascular health, subclinical atherosclerosis, and adverse cardiovascular events. The relationship between traditional risk factors and PCSK9 concentrations was also examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research